Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Nurix Therapeutics Reports First Clinical Evidence Of CNS Activity Of NX-5948, Orally Available, BTK Degrader In Development For B Cell Malignancies

Author: Benzinga Newsdesk | April 09, 2024 01:16pm

Presented new case studies demonstrating clinical responses in two patients with B cell malignancies, chronic lymphocytic leukemia (CLL) and primary central nervous system lymphoma (PCNSL), each with central nervous system (CNS) involvement

 

Data presented at the American Association for Cancer Research (AACR) 2024 Annual Meeting

Brain activity highlights potential for broader application of NX-5948 in autoimmune disorders with CNS involvement

Posted In: NRIX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist